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Multiple sclerosis (MS) is an autoimmune inﬂammatory demyelinating disease of the central nervous system and a major cause
of chronic neurological disability in young adults. Primary progressive MS (PPMS) constitutes about 10% of cases, and is
characterized by a steady decline in function with no acute attacks. The rate of deterioration from disease onset is more rapid than
relapsing remitting and secondary progressive MS types. Multiple system involvement at onset and rapid early progression have a
worseprognosis.PPMScancausesigniﬁcantdisabilityandimpactonqualityoflife.Recentstudiesarebiasedinfavourofrelapsing
remittingpatientsastreatmentisnowavailableforthemandtheyaremorelikelytobeseenatMSclinics.SinceprognosisforPPMS
is worse than other types of MS, the focus of rehabilitation is on managing disability and enhancing participation, and application
of a “neuropalliative” approach as the disease progresses. This chapter presents the symptomatic treatment and rehabilitation for
personswithMS,includingPPMS.Amultidisciplinaryapproachoptimizestheintermediateandlong-termmedical,psychological
and social outcomes in this population. Restoration and maintenance of functional independence and societal reintegration, and
issues relating to quality of life are addressed in rehabilitation processes.
1.Background
Multiple sclerosis (MS) is a chronic inﬂammatory demyeli-
nating disease of the central nervous system (CNS) aﬀecting
about 2.5 million persons’ worldwide [1]. It is the com-
monest cause of chronic neurological disability in young
adults. MS is complex and the exact pathogenesis is unclear.
The various disease courses in persons with MS (pwMS)
are shown in Box 1. One recent survey of 878 persons with
primary progressive MS (PPMS) [2] were found to have a
shortermediantimetodeathfromonsetandahigherrelative
risk of dying despite the fact that persons with PPMS live
for years with many disabilities that can cause limitation in
function and restriction in participation and impact quality
of life (QoL) [3].
ThenaturalhistoryofPPMSislesswellknowncompared
with other MS disease courses. Primary progressive MS
occurs in approximately 10% of pwMS and is primarily
progressive from onset. Approximately <5% of pwMS may
present with a progressive course although these patients
also experience occasional attacks, the progressive relapsing
MS type (PRMS) (see Box 1). The diagnostic criteria for
PPMS are shown in Table 1. It is thought to be diﬀerent
genetically from the relapsing remitting MS (RRMS) and in
MRI behaviour from secondary progressive MS type (SPMS)
[4, 5]. In PPMS, the paucity of MRI detectable disease
activity is in contrast with the observed accumulation of
irreversible disability [6]. Quantitative MRI studies [7]h a v e
highlighted the role of brain tissue damage outside T2 visible
lesions in the pathophysiology of PPMS.Kutzelnigg et al.
[8] showed that diﬀuse white matter injury and cortical
demyelination were hallmarks of progressive MS, occurring
on a background of a global “low burning” inﬂammatory
response with focal lesion load. The contribution of cord
damage to the severity and evolution of PPMS has also been
evident in several MRI studies [9, 10].2 Neurology Research International
Relapsing remitting MS (RRMS) occurs in 80% of MS cases at onset. It is characterized by relapses, which evolve over days
to weeks, with full recovery or with sequelae and residual deﬁcit upon recovery. Between attacks, the patient is
neurologically and symptomatically stable.
Secondary progressive MS (SPMS) may begin as RRMS, but at some point, the attack rate reduces and the course shows
steady deterioration in function unrelated to acute attacks.
Primary progressive MS (PPMS) accounts for 10% of cases at disease onset and is characterized by steady decline in
function from the beginning without acute attacks. These patients have a more even sex distribution, tend to have later age
of onset, and may have a worse prognosis for ultimate disability compared with those with RRMS.
Progressive relapsing MS (PRMS) (<5%) also begins with a progressive course although these patients also experience
occasional attacks.
Box 1: Types of MS. Adapted from Polman et al. [11].
Table 1: McDonald criteria for MS.
Clinical (Attacks) Objective
lesions Additional requirements to make a diagnosis
Two or more
Two or more, or
objective clinical
evidence of one
lesion with
reasonable
historical
evidence of a
prior attack
None
Two or more One
Dissemination in space, demonstrated by:
one or more T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular,
juxtacortical, infratentorial, or spinal cord) or await a further clinical attack implicating a
diﬀerent CNS site
One Two or more
Dissemination in time, demonstrated by:
simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at
any time; or A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective
of its timing with reference to a baseline scan or await a second clinical attack
One (clinically
isolated syndrome) One
Dissemination in space and time, demonstrated by:
for DIS:
one or more T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular,
juxtacortical, infratentorial, or spinal cord) or await a second clinical attack implicating a
diﬀerent CNS site and For DIT:
simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at
any time or a new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective
of its timing with reference to a baseline scan or await a second clinical attack
Insidious
neurological
progression
suggestive of MS
(PPMS)
One year of disease progression (retrospectively or prospectively determined) plus 2 of 3 of the
following criteria:
(1) evidence for DIS in the brain based on one or more T2 lesions in the MS-characteristic
(periventricular, juxtacortical, or infratentorial) regions,
(2) evidence for DIS in the spinal cord based on tow or more T2 lesions in the cord
(3) positive CSF (isoelectric focusing evidence of oligoclonal bands and/or elevated IgG index)
MS: multiple sclerosis; CNS: central nervous system; MRI: magnetic resonance imaging; DIS: dissemination in space; DIT: dissemination in time; PPMS:
primary progressive multiple sclerosis; CSF: cerebrospinal ﬂuid; IgG: immunoglobulin G. (Adapted from Polman et al. [12].)
TheoverallfemalepreponderanceinMSislessapplicable
to PPMS. The rate of deterioration from disease onset in
PPMS is more rapid, with higher relative mortality than
other MS types [13]. Those with shorter time from onset
to disability and those with involvement of three or more
neurological symptoms at onset have a worse prognosis
[14]. However prognosis in PPMS is not dependent on age,
gender, or type of neurological system involvement at onset.
A minority of people with PPMS can have a distinct relapse
even decades after onset of progressive deterioration [14].
Recent nonpopulation-based studies are biased towards
RRMS as treatment is now available for reducing the
number of relapses and delaying disease progression, so
they are more likely to be reviewed at MS clinics. All
suggested drug treatments for PPMS are empiric as there
is no convincing trial evidence of eﬀectiveness for diseaseNeurology Research International 3
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Figure 1: Components of international classiﬁcation of functioning disability and health. (Printed with permission: WHO-ICF [15].)
(i) Individualized patient centred treatment plan, with patient actively participating.
(ii) Prioritized goal setting through an interdisciplinary process.
(iii) Active patient participation to achieve set goals.
(iv) Goals should result in improvement in patients’ personal potential.
(v)Outcomes should demonstrate reduction in impairments and improvement in, activity and participation.
Box 2: Subcomponents of comprehensive rehabilitation. Adapted from: Steins et al. [16].
modifyingtherapy[17].AnindividualwithPPMS,therefore,
has limited drug therapy options and may beneﬁt from a
symptomatic and supportive rehabilitation approach aimed
at reducing symptoms and limitations at the level of activity
and participation.
Studies of pwMS have identiﬁed a range of impairments,
limitations in activity (disability), and restriction in partici-
pation using the World Health Organization’s International
Classiﬁcation of Functioning, Health, and Disability (ICF)
Figure 1 [15, 18, 19]. These ICF domains have complex
interactions and need evaluation and management through
holistic interventions, which include personal and environ-
mental factors. Recent MS expert consensus identiﬁed and
recommended the “Core” set (minimum data set) of ICF
categories for pwMS for comprehensive multidisciplinary
assessmentsinthedomainsofbodyfunction,bodystructure,
activities, and participation and environmental factors [18]
(Tables2–3).Muchoftheclinicalfocushastraditionallybeen
on the physical aspects of MS but improved understanding
of MS indicates involvement of multiple systems (cognition,
memory, and emotional control). The combined eﬀect of
these impairments in a pwMS leads to greater disability than
the sum of the individual impairments together. This may
explainwh ysomepwMSmaynotperformaswellasexpected
[20].
2. Rehabilitation
Rehabilitation is deﬁned as a problem solving educational
process aimed at reducing disability and limitation in par-
ticipation [21]. Rehabilitation interventions comprise expert
MD assessments evaluated through appropriate outcome
measures [22] using functional goal-oriented approaches
such as clinical pathways [23] to target patient priorities
[24]. Goal setting is an integral part of rehabilitation, as it
encourages participants to set their own goals and priorities,
and supports team communication and coordination. The
key subcomponents and phases of the rehabilitation process
[16] are shown in Boxes 2 and 3.
Existing clinical guidelines and frameworks [26, 27]
for PPMS recommend comprehensive, ﬂexible coordinated
multidisciplinary (MD) care and appropriate followup,
education, and support for patients and carers to address
the limitations in activity and participation levels. Key
issues for those severely aﬀected include respite, community
and/or long-term care, and community mobility. Early
referral for rehabilitation enables strategies to restore recent
functional deterioration [26]. In those severely aﬀected,
rehabilitation input can provide a modiﬁed environment
and adaptive equipment to restore some functional inde-
pendence. Caregiver education and support can reduce the
burden of care. Rehabilitation can address QoL issues and
direct care with other health professionals [28]. Impor-
tantly, “crisis management” should be avoided, planned
management of disability and deﬁcits should be anticipated
(over time), and appropriate mechanisms that accom-
modate and facilitate functional independence provided.
Some of the challenges to MS rehabilitation are shown in
Box 4.4 Neurology Research International
(i) Evaluation-identiﬁcation and quantifying eﬀects of disablement (limitation in activity and participation)—mediators for
adaptive capacity that can be targeted foci for therapy.
(ii) Treatments—arrest the pathophysiologic processes causing tissue injury.
(iii) Therapeutic exercise—focuses on enhancement of organ performance.
(iv) Task reacquisition—emphasizes total body adaptive techniques.
(v) Environmental modiﬁcation–directs eﬀort towards environmental enhancement (physical, psychological, social, and
Political) to improve participation.
Box 3: Phases in rehabilitation process. Adapted from: Steins et al. [16].
(i) MS is dynamic with a complex moving target of deﬁcits.
(ii) Unpredictable disease progression and lesion distribution makes it diﬃcult for the patient to adjust and use
compensatory strategies.
(iii) Covert symptoms (fatigue, diplopia) can be disabling but not visible to others.
(iv) Profound sense of vulnerability, loss of control, and grieving underlies the coping process.
Box 4: Challenges in MS rehabilitation.
3. Evidence for MS Rehabilitation
Ar e c e n ts y s t e m a t i cr e v i e ws u p p o r t st h ee ﬀectiveness of
MD rehabilitation programs in inpatient and ambulatory
settings in terms of improvements in activity (disability)
and participation [29]. Although there is evidence for
some unidisciplinary rehabilitation interventions for pwMS,
such as physical therapy [30], the evidence for others-
occupational therapy [31] and psychological therapies [32]
is less compelling. There is reasonable evidence to support
cognitive behaviour approaches for depression in helping
people adjust to, and cope with, having MS [33]. A recent
randomized controlled trial showed the duration of beneﬁt
of rehabilitation in reducing disability persists for about
12 months [34] but not the positive eﬀects on QoL and
emotional well-being. Eﬀects on QoL are often diﬃcult to
quantify in chronic conditions because of “response shift” or
thechangeininternalvalues,orconceptualizationofQoL,so
that pwMS may reassess their perceived limitations of daily
living and reset goals and consider the impact of their MS
less marked than they thought formerly [35]. More studies
are needed to assess impact of rehabilitation on QoL and
to understand the response shift phenomenon in the MS
population.
Further, in addition to randomized controlled trial
(RCT) methodology, a clinical practice improvement
approach has also been applied to an inpatient MS cohort
to understand the complex interplay of patient and process
factors and impact on functional outcomes in rehabilitation
for pwMS. In a pilot project (n = 24) [36], more than half
of pwMS had moderate to severe fatigue, deﬁcits in motor
function and mood causing signiﬁcant functional limitation,
and two thirds required specialized nursing (e.g., continence
care). Complexity of intervention was measured using the
Northwick Park therapy dependency assessment (NPTDA)
[37], which showed moderate dependency in physical,
cognitive, and psychosocial domains. The NPTDA scores
for these pwMS correlated strongly with FIM motor scores
(Spearman rho −0.80) and Barthel index (rho −0.83) [36].
Further prospective studies are planned using appropriate
tools to understand the “black box” of rehabilitation and the
complex inter relationships of factors which impact function
in this population.
Khan et al. [38] examined outcomes following inpatient
rehabilitation episodes (n = 1010) for pwMS using the
Australian Rehabilitation Outcomes Centre Database. The
majority of patients were female and following rehabilitation
discharged to the community. Improvement in function was
assessed using the functional independence measure (FIM),
with subclasses of pwMS based on motor FIM scores for
severityinfunctionallimitation.Authorsreportedsigniﬁcant
functional improvement (P = 0.001) with rehabilitation in
most MS groups, with year to year trend towards reducing
hospital length of stay and FIM eﬃciency although these did
not reach signiﬁcance.
4.NeuropalliativeApproachinPPMS
Since prognosis for PPMS is worse than other types of MS,
the focus of rehabilitation is on managing disability and
enhancing participation, and as disease progresses applying
a “neuropalliative approach” [25]. The UK guidelines for
managing long-term neurological conditions (LTNC) [39]
are relevant to PPMS as they explore interaction between
specialist neurology, rehabilitation, and palliative care ser-
vices and how they work together to provide long-term sup-
port for people with LTNC and their carers. The key skills in
neuropalliative care are shown in Table 4 [25]. Neurologists
assess, diagnose, and manage disease, and the palliative care
physicians’ manage distressing symptoms (nausea, vomiting,
and breathlessness), support and counsel the person and
family,end-of-lifeissues,andprovideadvancecareplanning.
Rehabilitation physicians contribute to care by managing
disability and provide adaptive aids (mobility and commu-
nication), procedures for spasticity management (botulinumNeurology Research International 5
Table 2: International classiﬁcation of functioning, disability, and health (ICF) categories for the components: body “function” and body
“structure” included in the “core” set for persons with MS for comprehensive multidisciplinary assessments.
ICF code ICF category title
Body function
B122 global psychosocial functions
B130 energy and drive functions
B144 memory function
B147 psychomotor function
B126 temperament and personality functions
B152 emotional functions
B164 higher level cognitive functions
B140 attention function
B160 thought functions
B114 orientation functions
B210 seeing function
B265 touch function
B260 proprioceptive function
B280 sensation of pain
B235 vestibular functions
B320 articulation functions
B330 ﬂuency and rhythm of speech functions
B310 voice functions
B455 exercise tolerance functions
B435 immunological system functions
B525 defecation function
B640 sexual functions
B620 urination functions
B760 control of voluntary movement functions
B750 motor reﬂex functions
B730 muscle power functions
B735 muscle tone functions
B755 involuntary movement reaction functions
B770 gait pattern functions
B710 mobility of joint functions
B780 sensations related to muscle and movement functions
B715 stability of joint functions
Body structure
S110 structure of brain
S120 structures spinal cord and related
S610 structure of urinary system
S720d structure of shoulder region
S730 structure of upper extremity
S750 structure of lower extremity
S760 structure of trunk
(Adapted from Khan and Pallant [18].)
toxin and phenol), and pain and behaviour management. As
disease progresses goal posts change and rehabilitation and
palliative approaches can overlap, that is, “neuropalliation”.
ManyissuesinPPMScanbemanagedbyclosercollaboration
and cross referral between the above specialties [40, 41].
The life circles diagram Figure 2 [25] shows the overlap
between roles of neurology, palliative care, and rehabilitation
physicians which are relevant to people with PPMS.6 Neurology Research International
Table 3: International classiﬁcation of functioning, disability and health (ICF) categories for the components: “activities and participation”
and “environmental factors” included in the “core” set for persons with MS for comprehensive multidisciplinary assessments.
ICF code ICF category title
Activities and participation
D160 focusing attention
D172 calculating
D175 solving problems
D220 undertaking multiple tasks
D240 handling stress and other psychological demands
D163 thinking
D166 reading
D177 making decisions
D230 carrying out daily routine
D210 undertaking a single task
D330 speaking
D350 conversation
D355 discussion
D345 writing messages
D315 communicating with-receiving-nonverbal messages
D310 communicating with-receiving-spoken messages
D360 using communication devices and techniques
D335 producing nonverbal messages
D325 communicating with-receiving-written messages
D415 maintaining a body position
D420 transferring oneself
D445 hand and arm use
D450 walking
D455 moving around
D410 changing basic body position
D430 lifting and carrying objects
D440 ﬁne hand use
D460 moving around in diﬀerent locations
D456 moving around using equipment
D470 using transportation
D475 driving
D510 washing oneself
D530 toileting
D540 dressing
D550 eating
D520 caring for body parts
D560 drinking
D570 looking after one’s health
D630 preparing meals
D640 doing housework
D650 caring for household objects
D620 acquisition of goods and services
D770 intimate relationships
D710 basic interpersonal interactions
D720 complex interpersonal interactionsNeurology Research International 7
Table 3: Continued.
ICF code ICF category title
D740 formal relationships
D760 family relationships
D750 informal social relationships
D850 remunerative employment
D845 acquiring keeping and terminating a job
D870 economic self suﬃciency
D825 vocational training
D855 nonremunerative employment
D860 basic economic transactions
D920 recreation and leisure
D910 community life
D930 religion and spirituality
Environmental Factors
E120 products or technology for personal indoor/outdoor
mobility and transportation
E135 products and technology for employment
E115 products or technology for personal use in daily living
E125 products and technology for communication
E130 products and technology for education
E155 design,construction,buildingproducts,andtechnology
of buildings for private use
E150 design,construction,buildingproducts,andtechnology
of buildings for public use
E110 products or substances for personal consumption
E165 assets
E225 climate
E210 physical geography
E310 immediate family
E320 friends
E355 health professionals
E340 personal care providers and personal assistants
E360 health related professionals
E325 acquaintances, peers colleagues, neighbours, and com-
munity members
E330 people in positions of authority
E315 extended family
E410 individual attitudes of immediate family members
E420 individual attitudes of friends
E450 individual attitudes of health professionals
E455 individual attitudes of health related professionals
E425 individual attitudes of acquaintances, peers colleagues,
neighbours, and community members
E440 individual attitudes of personal care providers and
personal assistants
E460 societal attitudes
E430 individual attitudes of people in positions of authority
E570 social security services, systems, and policies
E575 general social support services, systems, and policies
E525 housing services, systems, and policies
E540 transportation services, systems, and policies8 Neurology Research International
Table 3: Continued.
ICF code ICF category title
E590 labour and employment services, systems, and policies
E530 utilities services, systems, and policies
E510 services, systems and policies for the production of
consumer goods
E515 architecture and construction services, systems, and
policies
E580 health services, systems, and policies
(Adapted from Khan and Pallant [18].)
Table 4: Key skills in neurological palliative care and rehabilitation.
Every physician should have an understanding of the general principles of management and should also be aware of when and where to refer
if more specialist advice is needed in the areas shown below
Exposure to people
with long-term
neurological
conditions
(i) Understanding disease progression and prognosis
Symptom control
(i) Ability to control key symptoms including:
(1) pain in neurological conditions
(2) breathlessness
(3) nausea/vomiting
(4) anxiety/depression
(5) spasticity management
( 6 )2 4h o u rp o s t u r a ls u p p o r t
(7) Bladder and bowels
(8) Seizure control
Communication
(i) Basic understanding of common communication problems including dysphasia, dysarthria, cognitive
speech disorders, and the diﬀerent approaches to their management.
(ii) Ability to communicate with people who have cognitive/communication impairments
(1) using assistive communication devices
(iii) Communicating with patient and family
(1) breaking bad news
(2) addressing end of life decisions and advance care planning which will include choice over place of
care.
(3) Managing expectations.
Legal issues
(i) Ability to assess for mental capacity and to assist people to make advance decisions and statements.
(ii) Understanding of the Mental Capacity Act 2005 and ability to work alongside lasting power of
attorney/court appointed deputy or independent mental capacity advocates.
Additional skills for physicians specializing in neurological palliative care and rehabilitation
Specialist
interventions
(i) Local and intrathecal interventions for spasticity (e.g., injection of botulinum toxin/phenol and use of
baclofen pumps).
(ii) Specialist procedures for pain control.
(iii) Management of confusion/unwanted behaviours–management under sections of the Mental Health Act
1983
(iv) Ventilation
Specialist equipment
(i) Wheelchair seating systems
(ii) Environmental control systems
(iii) Specialist communication aids
Counselling and
psychological support
(i) Dealing with loss and fear of loss
(ii) Spiritual support
(iii) Bereavement–past and future
Welfare advice (i) Understanding the social care system and beneﬁts
(ii) Vocational support
Additional sources of
help and support
(i) Understanding the interaction between health, social services and voluntary support agencies
(ii) Negotiating skills in obtaining services
(Printed with permission: RCP 2008 [25].)Neurology Research International 9
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Figure 2: Life overlap diagram: interface between neurology,
rehabilitation and palliative care in the management of persons
with long-term neurological conditions and primary progressive
multiple sclerosis. (Printed with permission: Turner-Stokes et al.
[41].)
5. Symptomatic Management
andRehabilitation
This section outlines the symptomatic and disability manage-
ment of persons with MS, including PPMS. As PPMS is a
progressivedisease,regularpatientevaluationandreassessment
of treatment and management is required. The rehabilitation
intervention principles and “neuropalliation” apply to this
patient population. The management strategy includes educa-
tion, therapy input, and medications.
PPMS presents primarily as progressive disease at onset;
however, a minority may present with an acute relapse with
a wide range of symptoms and signs. The most common
patient reported symptoms that have a disabling impact
are fatigue, mobility-related issues, and bladder and bowel
dysfunction.Onestudyof101pwMSshowedthe“linkage”of
patientreportedMSrelatedproblemsanddegreeoflimitation
caused using the WHO ICF categories for the components:
Body structure, Body Function, Activities and Participation,
and Environmental factors [19], Table 5.
5.1. Disabilities in MS
5.1.1.Fatigue. Fatigueisoneofthemostcommonsymptoms
in MS reported by up to 95% of pwMS. It is deﬁned
as “subjective” lack of physical or mental energy that is
perceived by the individual or caregiver to interfere with
usual activities and is present 60% of the time. In a sample
of 656 patients with MS, 22% reported limitation in level of
physical activity, 14% stated it required them to have more
frequent rest breaks and 10% had to discontinue work due
to fatigue [50]. Fatigue impacts on ability to work, social
life and on activities of daily living. It is however diﬃcult to
predictandisunrelatedtoage,gender,disabilityasmeasured
by Kurtzke Expanded Disability Status Scale (EDSS) [51]
score or Neuro imaging status. Factors believed to contribute
to fatigue in MS are summarized in Box 5.
There are a number of measures of MS-related fatigue
[48] (see Table 6).
Treatment of fatigue should be individualized based
on the medical and functional status of each patient. The
quality and quantity of fatigue, and its impact on function
is obtained on history. Other non-MS causes should be
excluded (anaemia and hypothyroidism) and contributing
factors identiﬁed. Medications and side eﬀects should be
reviewed. Nonpharmacologic approaches include education
for patient and family (avoid heat, use airconditioners, and
cooling gel vests), address lifestyle factors, for example, diet
and exercise, avoid physical activity at mid afternoon (as a
s m a l lr i s ei nc o r eb o d yt e m p e r a t u r ew o r s e n sf a t i g u ea n dM S
lassitude or lack of energy). Fatigue management and pacing
(regular rest breaks between activities, i.e., pacing activities
throughout the day), energy conservation, and work sim-
pliﬁcation strategies to decrease energy consumption and
increase economy of eﬀort (use of assistive devices, adaptive
equipmentsuchaslonghandledaids/grabrails,gaitaidssuch
as a walking frame, and ankle foot orthoses to improve gait
eﬃciency) and improve overall ﬁtness by structured exercise
programs for aerobic capacity and endurance.
There is limited evidence supporting drug eﬃcacy in
MS related fatigue. Modaﬁnil, a “wake promoting” agent
that selectively works in the hypothalamic pathways, has
been reported to improve fatigue in progressive MS. Amino
pyridines (potassium channel blockers) and amantadine (N-
methyl D-aspartate receptor antagonist) have been used,
howeversystematicreviewsfailedtoﬁndevidenceforeﬃcacy
or safety of their use [52]. Depression may contribute to
fatigue in some cases and there is empiric support for use
of antidepressants in MS related fatigue. A clinical decision
making ﬂowchart for managing fatigue in MS is shown in
Figure 3 [48].
5.1.2.Bladder,Bowel,andSexualDysfunction. Abnormalities
in bladder function are primarily neurogenic and occur in
over 80% of patients. Bladder dysfunction has a detrimental
impact on mobility, everyday living activities, and on QoL
in pwMS [53]. A recent RCT (n = 74) showed eﬀectiveness
of multidisciplinary rehabilitation for individualized blad-
der management program [54]. Approximately two thirds
of patients on functional studies demonstrate overactive
detrusorfunction,whiletheremainderexhibitunderactivity.
The external urethral sphincter complex may be synergic
or dyssynergic with bladder contraction. Detrusor sphincter
dyssynergia increases risk of pyelonephritis and renal failure
due to combined eﬀects of back pressure and reﬂux of
infected urine into the kidney. Symptoms are unreliable in
determining the precise underlying functional abnormality.
Risk factors for progressive upper urinary tract dysfunction
in MS, which require longer-term followup include: detrusor
sphincter dyssynergia, age over 50 years, and male gender
[55].
Urodynamic studies are mandatory to evaluate the
pattern of neurogenic bladder dysfunction in an individual.
On a day-to-day basis, general techniques for managing10 Neurology Research International
Table 5: Frequency of limitations reported by persons with MS (N = 101) linked with ICF categories for the components: body function,
body structure, activity and participation, and environmental factors (those reported by at least one third of MS patients are listed below).
ICF code Chapter title ICF code description
Total number of
participants linked
responses. n,%
Number of participant and stage of disease
RR SP PP rr-SP
Body function
b130 Global mental
functions Energy and drive functions 98, 97.03 51 26 14 7
b134 Sleep 84, 83.17 47 21 11 5
b140 Speciﬁc mental
functions Attention 66, 65.35 37 17 9 3
b144 Memory 62, 61.39 37 16 4 5
b152 Emotional functions 97, 96.04 50 26 14 7
b210 Seeing and related
functions Seeing 47, 46.53 24 16 4 3
b235 Hearing vestibular Vestibular (incl. balance
functions) 71, 70.30 34 19 13 5
b265 Sensory functions Touch 34, 33.66 15 10 7 2
b280 Pain Sensation of pain 76, 75.25 39 19 12 6
B455 CVS and respiratory
functions
Exercise tolerance
functions∗ 97, 96.04 50 27 13 7
b525 Digestive system Defecation 89, 88.12 49 21 14 5
b620 Urinary functions Urination functions 94, 93.07 50 24 13 7
b640 Genital and
reproductive Sexual functions 57, 56.44 32 15 7 3
b730 Muscle functions Muscle power 96, 95.05 50 27 13 6
b735 Muscle tone 94, 93.07 50 26 13 5
b740 Muscle endurance
function∗ 93, 92.08 49 25 12 7
b760 Movement functions Control of voluntary
movement functions∗ 66, 65.35 37 18 8 3
b770 Gait pattern functions∗ 99, 98.02 51 27 13 8
Body Structure
s110 Nervous system Brain 100, 99.01 50 28 14 8
s610 Genitourinary system Urinary system 93, 92.08 49 25 12 7
s730 Structures related to
movement
Upper extremity (arm,
hand) 44, 43.56 25 10 7 2
s750 Lower extremity (leg, foot) 97, 96.04 49 27 14 7
s760 Trunk 85, 84.16 44 23 12 6
Activities and participation
d160 Applying knowledge Focussing attention 70, 69.31 39 16 9 6
d175 Solving problems 34, 33.66 22 8 2 2
d177 Making decisions 59, 58.42 35 16 5 3
d220 General tasks and
demands Undertaking multiple tasks 88, 87.13 47 24 12 5
d230 Carrying out daily routine 80, 79.21 48 17 10 5
d240 Handling stress and other
psychological demands 101, 100.00 51 28 14 8
d430 Mobility Lifting and carrying
objects 53, 52.48 30 12 8 3
d440 Fine hand use (picking up,
grasping) 51, 50.50 26 13 9 3Neurology Research International 11
Table 5: Continued.
ICF code Chapter title ICF code description
Total number of
participants linked
responses. n,%
Number of participant and stage of disease
RR SP PP rr-SP
d445 Hand and arm use 37, 36.63 21 9 4 3
d450 Walking 101, 100.00 51 28 14 8
d455 Moving around∗ 99, 98.02 51 27 14 7
d465
Moving around and
using equipment
(wheelchair, skates, etc.)
98, 97.03 50 27 14 7
d470
Using transportation
(car, bus, train, plane,
etc.)
100, 99.01 51 27 14 8
d475
Driving (riding bicycle
and motorbike, driving
car etc.)
99, 98.02 51 27 14 7
d510 Self care
Washing oneself
(bathing, drying,
washing hands, etc.)
41, 40.59 26 9 4 2
d520
Caring for body parts
(brushing teeth, shaving,
grooming, etc.)
40, 39.60 24 8 5 3
d570 Looking after one’s
health 88, 87.13 47 23 14 4
d620 Domestic life Acquisition of goods and
services (shopping, etc.) 92, 91.09 50 24 12 6
d630 Preparation of meals
(cooking etc.) 89, 88.12 48 24 12 5
d640
Doing housework
(cleaning washing,
laundry, and ironing)
94, 93.07 51 23 14 6
d650 Caring for household
objects∗ 84, 83.17 46 22 12 4
d660 Assisting others 87, 86.14 48 22 13 4
d750 Interpersonal
relationships
Informal social
relationships 35, 34.65 19 12 2 2
d760 Family relationships 73, 72.28 42 16 11 4
d770 Intimate relationships 61, 60.40 35 15 7 4
d845 Work Acquiring keeping and
terminating a job∗ 73, 72.28 39 19 11 4
d850 Remunerative
employment 90, 89.11 45 24 13 8
d870 Economic life Economic
self-suﬃciency 84, 83.17 44 22 13 5
d910 Community life Community Life 79, 78.22 40 21 13 5
d920 Recreation and leisure 97, 96.04 50 26 14 7
Environmental Factors
e110 Products and technology
For personal
consumption (food,
medicines)
101, 100.00 51 28 14 8
e120
For personal indoor and
outdoor mobility and
transportation
91, 90.10 47 25 12 7
e150
Design, construction
and building products
and technology of
buildings for public use
70, 69.31 39 18 9 412 Neurology Research International
Table 5: Continued.
ICF code Chapter title ICF code description
Total number of
participants linked
responses. n,%
Number of participant and stage of disease
RR SP PP rr-SP
e210 Natural environment Physical geography∗ 39, 38.61 21 11 5 2
e225 Climate 99, 98.02 50 28 14 7
e310 Support and
relationships Immediate family 45, 44.55 27 9 7 2
e315 Extended family∗ 42, 41.58 26 9 3 4
e460 Attitudes Societal attitudes 31, 30.69 13 9 5 4
e540 Services, systems, and
policies
Transportation services,
systems and policies 68, 67.33 38 17 8 5
e580 Health services, systems
and policies 79, 78.22 45 18 11 5
(Adapted from Khan and Pallant [19].)
Table 6: Measures of multiple sclerosis related fatigue.
Name of scale Author, year [ref.] Population Speciﬁed fatigue
subscales No. of items Scoring
Modiﬁed fatigue
impact scale
Paralysed Veterans of
America 1998 [42] MS Physical, cognitive
and psychosocial 21 Likert scale
Rochester fatigue
diary
Schwid et al., 2002
[43] MS Lassitude (reduced
energy)
12 (1 item, 12 times
over 24h) Visual analogue scale
Fatigue descriptive
scale Iriarte et al., 1999 [44]M S
Spontaneous mention
of fatigue, antecedent
conditions, frequency,
and impact on life
50 – 3
Fatigue impact scale Fisk et al., 1994 [45]M S Physical, cognitive,
and psychosocial 21 0–4
Fatigue assessment
instrument
Schwartz et al., 1993
[46]
Lynne, Chronic
fatigue syndrome,
lupus, Ms, dysthymia,
healthy
Fatigue severity,
situation speciﬁcity,
consequences of
fatigue, and responds
to rest/sleep
29 1–7
Single item visual
analogue scale of
fatigue
Krupp et al., 1989
[47] MS, lupus, healthy None 1 Visual analogue scale
Fatigue severity scale Krupp et al., 1989
[47] MS, lupus, healthy None 9 Likert scale
(Adapted from: MacAllister and Krupp [48].)
Primary factors
(i) Immune dysregulation—changes in neuroendocrine function.
(ii) Central nervous system mechanisms—neuronal dysfunction due to immune injury, demyelination and inﬂammation,
impaired innervation, and activation of muscle groups leading to compensatory increase in central motor drive exertion and
more energy depletion.
(iii) Endocrine factors—abnormalities in hypothalamic/pituitary/adrenal axis.
(iv) Neurotransmitter dysregulation—dopaminergic, histaminergic, and serotonergic pathways may contribute to fatigue.
Secondary factors.
(i) Physical deconditioning from failure to get adequate exercise.
(ii) Sleep dysfunction—may also be due to nocturnal spasms, pain, incontinence, and depression.
(iii) Pain—sensory disturbances, neuralgia, dysesthesia, and spasms.
(iv) Depression—in closely related to poor sleep, pain, and fatigue.
(v) Medications—can worsen fatigue (antispasticity agents, e.g., Baclofen).
Box 5: Primary and secondary factors in multiple sclerosis fatigue. (Adapted from: MacAllister and Krupp [48]).Neurology Research International 13
Is fatigue present?
Yes
Yes
No
No
If possible, eliminate/reduce medications
Is depression evident?
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Consider medications
mantadine and modaﬁnil
Energy
conservation
and pacing
strategies
Work
simpliﬁcation
strategies
Treat depression
with psychotherapy
and/or
antidepressants(s)
Consider
nonpharmacological
interventions
Education
(patient and
caregiver)
Life style
modiﬁcation
(exercise
and diet)
Environmental
modiﬁcation
(adaptive aids
e.g., cooling
vests)
a
Figure 3: Clinical decision making ﬂow chart for treating fatigue in MS. (Adapted from: MacAllister and Krupp [48].)
bladder care include scheduled ﬂuid intake, timed voiding
pattern, establishment of emptying techniques every three
hours (tapping over suprapubic region, Credes maneuver),
use of pads and undergarments, and use of bedside com-
mode or urinal. Other simpler techniques such as voided
volume charts will provide evidence of small frequent urine
volumes suggesting detrusor hyperactivity. Postmicturition
ultrasound should be performed regularly and if residual
volumes exceed 100mL, a regimen of intermittent clean self-
catheterisation should be introduced. If this is not possible
duetoupperlimbdysfunctionoradductorspasm,long-term
catheterisation should be considered.
Detrusor overactivity can be treated with anticholiner-
gic medications (oxybutynin, imipramine, solifenacin, and
tolterodine) and in severe cases with intravesical oxybutynin
or botulinum toxin. Additional techniques for managing
bladder include scheduled ﬂuid intake, prompted voiding,
avoidance of alcohol and caﬀeine, pelvic ﬂoor exercises
and other behaviour modiﬁcations. For detrusor sphincter
dysynergia regular attempts to void (light tapping), trial of
antispasticity agents (baclofen), alpha adrenergic blocking
agents (prazosin and clonidine), and anticholinergic med-
ications (oxybutynin) with intermittent catheterization can
be trialed. Detrusor underactivity causes incomplete bladder
emptying and can be managed with intermittent catheteri-
zation; if these are unsuccessful, an indwelling catheter may
be needed. Suprapubic catheterisation is preferable than
urethral catheterization, as they have fewer complications
includingurinaryinfections,areeasiertochange,andpermit
normal sexual functioning. Figure 4 provides a ﬂow chart for
managing urinary incontinence in patients with long-term
neurological conditions including PPMS [39].
Symptomatic lower urinary tract infections should be
treated on the basis of a positive urine culture. Acidifying
agents such as cranberry can reduce risk of recurrent
urinary infections in neurogenic bladders. Symptomatic
management of lower urinary tract symptoms includes the
antidiuretic hormone desmopressin (DDAVP) nasal spray
for nocturia and oral cannabinoids. Bladder retraining
and pelvic ﬂoor exercises may be useful if patients are14 Neurology Research International
Spontaneous voiding but incontinent:
settling for catheterisation
U/S
Residual volume Intermittent catheterisation
At least once daily
Exclude obstruction,
( f not possible, may require
insipidus, chronic renal failure,
- Incomplete chart
- Insuﬃcient ﬂuid intake
Voided volume
charts × 3
Total volume
Encourage more frequent emptying;
If necessary with intermittent catheterisation
Small and frequent
Voided volumes
Large
Voided volumes
Exclude UTI
If no dyssynergia but detrusor over-
activity consider:
- Botulinum toxin to detrusor
Consider sphincter dyssynergia or other causes of outﬂow obstruction,
e.g., stones, urethral stricture or prostatic hypertrophy
- U/S upper tracts to exclude dilatation
- Urodynamics to assess pressures
- Urological advice
Failure to establish urinary continence
e.g., upper limb dysfunction
Intermittent catheterisation
detrusor overactivity
Consider botulinum toxin
urethral sphincter to
establish no remediable cause before (>50–100mL)
Increased: >2000mL
Consider: diabetes, diabetes
Decreased: <2000mL
as required to keep voided volumes <500mL
(<300mL) (>500mL)
- Anticholinergics (e.g.,
solifenacin)
As required to keep volumes <500mL
i
Postmicturition
long-term catheterisation)
diuretics, and obsessive drinking
oxybutynin, tolterodine, and
Long-term catheter:
- Suprapubic preferable
with anticholinergics if associated
constipation, drugs, and so forth
Figure 4: Managing urinary incontinence in patients with long term neurological conditions including primary progressive MS. (Printed
with permission: RCP 2008 [25].)
appropriately educated in conjunction with a physiother-
apist. Patients should be provided with tips to prevent
recurrent urinary infections such as awareness of signs of
infection (cloudy urine or pain and odor), adequate ﬂuid
intake (8 glasses per day), increase urine acidity (vitamin C)
or cranberry capsule daily, try to achieving complete bladder
emptying, wiping front to back after going to the bathroom,
and regular change of indwelling catheters (4–6 weekly).
Bowel dysfunction has been reported in 50% of pwMS,
with constipation, and faecal incontinence. These result
from autonomic dysfunction and abnormal rectal function.
Absent rectal sensations increase risk of faecal incontinence,
which can reﬂect decreased rectal ﬁlling sensation, poor
sphincter and pelvic ﬂoor contraction and decreased rectal
compliance. A recent study identiﬁed female sex, higher
disability,andurinarydysfunctionasindependentpredictors
of developing anorectal dysfunction [56]. Bowel programs
need to be eﬀective (i.e., complete within 60 minutes
from beginning of program to bowel evacuation). Patient
education includes review of diet and bowel habits. The
optimization of consistency of bowel contents is ensured
by adequate oral intake, a diet high in ﬁbre and laxatives
(bowel softeners such as coloxyl) if necessary. Next is
the facilitation of the movement of the bowel contents, a
combination of osmotic (e.g., lactulose) and stimulants (e.g.,
senna) is eﬀective and is the mainstay medical treatment.
The iso-osmotic laxative polyethylene glycol (Movicol) has
been shown to be eﬀective in chronic constipation and is
used in resistant cases. Frequent use of enemas should be
avoided. The timing of a bowel program ideally should be
postprandial when the gut is most active. Rectal stretching
(suppository) can facilitate the defecation reﬂex and assist
bowel evacuation. A ﬂow chart outlining bowel management
in pwMS is shown in Figure 5.
Sexual dysfunction in MS has been widely reported
especially in patients with urinary symptoms [57]. Causes
of sexual dysfunction may be primary (lack of lubrica-
tion, diminished genital sensations, erectile dysfunction),
secondary (spasticity, pain, catheter care) or tertiary (marital
diﬃculty, fear, and lack of conﬁdence and self-worth). MenNeurology Research International 15
General measures
• Establish regular bowel regimen
◦ Scheduled evacuation times
• Assure adequate daily dietary ﬁbre (15g) daily
◦ High ﬁbre foods (fruits, vegetables,
and grains)
Constipation
• Start by cleaning out the bowel
• Use dietary triggers (100% brain, fruit and apple juice,
• Oral medications
◦ Bulk forming agents
docusate/casanthrand)
◦ Smooth muscle stimulants (senna) 6–8 hours
before evacuation
◦ Mild laxatives
• Local stimulant
◦ Digital stimulation
• Local evacuants
◦ There vac mini enema and ﬂeet enema
• Systemic stimulants
◦ Magnesium citrate
• Biofeedback retraining
Faecal incontinence
• Bowel training regimen/programmed evacuation
times
◦ Avoid chronically distended rectum
• Appropriate diet
• Suppositories to evacuate rectum
• Anticholinergic medications
• Surgical manoeuvres
◦ Rectal bag
◦ Artiﬁcial sphincter
Diarrhoea
• Skin care
• Replace ﬂuid loss
• Medications to decrease GI mobility
(antidiarrheals)
• Bulk forming supplements
• Biofeedback retraining
m
b
◦ Supplements (psyllium and etamucil)
◦ Suppositories ( isacodil and glycerin)
◦ Avoid rice, cheese, and excess protein
and other ﬂuids/foods)
◦ Stool softeners (docusate sodium and
• Monitor diet, weight, and electrolytes
• Assure adequate daily hydration (1.5–2 litres)
Figure 5: Management of bowel problems in MS. (Adapted from: Miller et al. [49].)
commonly report diminished libido, erectile and ejaculatory
dysfunction. Women report diminished genital sensation,
lubrication, and diﬃculty achieving orgasm. Rehabilitation
includes education about intimacy and sexuality, manage-
ment of fatigue, positioning, and mechanics, information
about aids (tumescence devices), speciﬁc suggestions and
techniques, and referral for sexual counselling. The use
of oral phosphodiesterase inhibitors (e.g., sildenaﬁl) have
been successful in treating erectile dysfunction in men; their
role in women has not been established. In addition to
intracorporeal pharmacotherapy, papaverine has now been
replaced by prostaglandin E1 by intracavernosal injection or
urethral application.
5.1.3.MobilityRelatedSymptoms. Mobility can be aﬀectedin
MS from a combination of motor (weakness and spasticity),
sensory (proprioception loss, ataxia), fatigue, and visual
impairments.
Spasticity. Spasticity, a velocity-dependent increase in mus-
cle tone, is a common complication of MS. Muscle short-
ening and restricted movements lead to decreased tissue
compliance and biomechanical diﬃculties (contractures)
which can limit a person’s activity (mobility, ability to
transfer, perform self-care tasks, and pain) and participation
(unable to drive or work). Management of spasticity in
pwMS is complicated due to lesions in the brain and spinal
cord, numerous other secondary MS-related impairments,
and their associated polypharmacy. There are limited studies
which do not suggest improved outcomes of one strategy
for managing spasticity compared with another. Two useful
measure of spasticity include the spasm frequency scale
[58] and the modiﬁed ashworth scale [59]. The spasm
frequency scale is obtained from history, and is a 0–4 non
interval scale: 0: no spasms, 4: 10 spontaneous spasms per
hour. The modiﬁed ashworth scale is obtained after clinical
examination and is also a non interval scale of 0–4 (although
it includes a value for 1+), with 0: “no increase in tone”, 4:
“aﬀected part is rigid”. More recently, a systematic review
found the Tardieu scale to be a more sensitive measure for
spasticity;however,furthervalidityvalidationofthisscalefor
v a r i o u sm u s c l eg r o u p si sr e q u i r e d[ 60].
The treatment goals change with progression of disease.
Early in the courseof the disease, spasticity caninterferewith
functional activities and also cause gait ineﬃciency, which in16 Neurology Research International
turnincreasesfatigue.Ontheotherhand,asmusclesweaken,
some patients rely on their spasticity to keep them on
their feet. Carefully targeted intervention for those elements
of spasticity that are unwanted can assist with energy
conservation and so keep pwMS mobile and independent for
longer.Lateron,thefocusoftreatmentismoreonimproving
ease of maintaining hygiene, prevention of contractures and
pain reduction. Management involves patient education,
therapy intervention, and medication [28]. The aims of
therapy are awareness of symptoms related to spasticity and
awareness of factors that can worsen spasticity for exam-
ple, noxious stimuli, sudden movements, anxiety; correct
positioning and alignment, and a stretching program. The
mainstay of treatment is maintaining muscle length, so the
importance of positioning and physical management (such
as a regular standing regimen) cannot be over-estimated.
Drugs are an adjunct to these interventions and may be
given orally or by intramuscular, intraneural, or intrathecal
injection.
Oral antispasticity agents are ﬁrst-line therapy for gen-
eralised spasticity [28]. The most commonly prescribed
oral agents include baclofen, tizanidine, clonazepam, and
dantrolene. Baclofen (gamma amino butyric acid agonist)
remains the agent of ﬁrst choice though its use is restricted
by side eﬀects including weakness, fatigue, and cognitive
impairment. Tizanidine (central acting α2 adrenergic ago-
nist) can be used in conjunction with baclofen or in
isolation in patients who cannot tolerate or have no response
to baclofen. Clonazepam (benzodiazepine) is particularly
eﬀective at treating nocturnal spasms. Its side eﬀect proﬁle
includes sedation and eﬀects on cognition. Dantrolene acts
at the level of the muscle and can be used with any of
the above agents for severe generalized spasticity. Its use
is limited by its side-eﬀect proﬁle and poor tolerability. 4-
Aminopyridine (Dalfampridine and Fampridine) (voltage-
gated potassium channel blocker) has been shown to provide
improvement in lower limb function, but toxicity with
seizures and encephalopathy can occur at therapeutic doses
[61, 62]. Other pharmacological agents such as Memantine
did not show any beneﬁt in treatment of spasticity [63].
Cannabis extracts are reported to have positive eﬀect on
spasticity and can be prescribed orally or via nasal spray
[28]. Cannabinoids act on CB1 receptors in the CNS to
inhibit cyclic AMP and voltage-dependent calcium channels,
causing antispastic eﬀect.
Intrathecal Baclofen (ITB) is eﬀective for severe gener-
alised spasticity, particularly in the lower limbs. It requires
lower doses and has improved tolerability due to less
sedative and cognitive side eﬀects. However, ITB withdrawal
syndrome (incorrect dosage and pump failure) can be
life threatening, and therefore, this treatment should only
be managed in specialist units [64]. For focal spasticity,
botulinum toxin injected into the aﬀe c t e dm u s c l e ( s )c a nb e
eﬀective [65]. Other localized spasticity (adductor muscles)
can be treated with phenol neurolysis. Surgical options
(tendon release surgery) are reserved for severe spasticity,
causing pain, interfering with care, and/or limiting activities
of daily living.
Ataxia. Cerebellar problems such as tremor, ataxia, and
incoordination are common in pwMS. The action (postural-
intention) tremor reﬂects brainstem-cerebellar circuitary
lesions and can be disabling and is often diﬃcult to treat.
Symptomatic treatment for tremor includes identiﬁcation of
type of tremor, trigger factors and part of body involved. Use
of assistive devices (braces and support) and evaluation for
therapy may be helpful. Limited beneﬁt from drug therapy
using Ondansetron (for cerebellar tremor), propanolol, and
combined therapy with lamotrigine and gabapentin have
been reported. Surgical ablative and stimulation techniques
(ventral intermediate thalamic nucleus) are currently being
trialed.
Truncal ataxia can occur in up to 70% of pwMS,
often accompanied by tremor. It has a signiﬁcant eﬀect on
motorcoordination(similartoweakness)andinterfereswith
balance and mobility, increasing predisposition to falls and
injury. Patient education and safety in daily living tasks
is emphasized as rehabilitation strategies, which include
improvement in posture and alignment, proximal stabiliza-
tion (pectoral and pelvic girdle musculature), coordination
exercises, and assistive devices such as the use of distal
weights around the wrists to dampen tremor and the use
of walking frames or elbow crutches enhance gait stability.
Falls prevention strategies and environmental modiﬁcation
(installation of grab rails, nonskid ﬂoor mats) can be helpful.
In one small RCT (n = 23) [66], pwMS were randomized
to speciﬁc physiotherapy strategies such as (a) facilitation
therapy (individualized, passive and active manual assis-
tance,posturalcontrol,andcomponentpracticeasinBobath
technique)and(b)taskorientedtherapy(nonindividualized,
hands oﬀ acceptance of compensatory strategies and func-
tional tasks such as stair climbing and treadmill walking).
Although patients in both groups showed improvement in
gait scores, balance tests and global mobility indices, those
in the facilitation group had nonsigniﬁcant trends towards
greater beneﬁt in all categories. Medications for ataxia
are similar to those used for treating tremors (isoniazid,
clonazepam, propanolol, gabapentin, and Ondansetron). A
recent systematic review found no evidence that medication
or neurorehabilitation strategies provide sustained improve-
ment in ataxia in pwMS [67]. Surgical interventions such as
thalamotomy or thalamic stimulation in MS have produced
limited success.
5.1.4. Pain and Paroxysmal Symptoms. Pain can be acute
or chronic. The underlying mechanisms of pain in MS are
unclear and have been linked with the diﬀerentiation and
disinhibition of central and pain pathways [68, 69]w i t h
CNS lesions causing hyperexcitability and with increased
neuronal activity at the site of the lesion in the spinal cord
[70]. Acute pain may be associated with active inﬂammatory
process. Chronic pain may be due to the MS process itself
or from complications that arise from it such as trigeminal
neuralgia, spasms/spasticity, and musculoskeletal posture
and gait-related problems [71].
In one recent Australian series (n = 94) 60% of patients
reported chronic pain, of these 61% had dysesthetic pain and
70% had episodic increases in pain [72]. Chronic pain inNeurology Research International 17
MS impacts on activities of daily living [71] and interferes
with ability to work [73]. A recently published study (n =
62) performed cluster analysis to classify patients into three
cognitive behavioral groups (adaptive copers, dysfunctional
and interpersonally distressed) and suggested possible cut
points to aid clinicians in classifying patients into clusters for
individualized treatment [74]. The severity of depression is
reported to be higher in persons with MS with chronic pain
than those without pain. There is also increased interference
with daily activities, more severe symptoms of depression
and negative eﬀect on relationships with partners and family
[71].Treatmentofchronicpainhasbeendiscussedelsewhere
[75]. A multidisciplinary team approach may be needed and
referral to pain clinic may be helpful.
A systematic approach initially using monotherapy to
maximumdosesbeforepolytherapyisimperativeAmitripty-
line is eﬀective for chronic dysesthetic pain. Carbamazepine
is the drug of choice for trigeminal neuralgia if not toler-
ated then alternatives include gabapentin, lamotrigine, and
phenytoin [76]. Transcutaneous electrical nerve stimulation
to lower back of pwMS appears promising [77]. Surgical
options are percutaneous procedures and rarely microvascu-
lar surgery [78]. Carbamazepine and gabapentin are agents
of choice for other paroxysmal symptoms (tonic spasms,
ataxia, or sensory symptoms like Lhermitte’s). Cannabis-
based preparations are eﬀe c t i v ef o rp a i ni np w M S[ 79]
but are reserved for cases where standard therapies have
failed or are not tolerated. There is no evidence to support
routine use of intrathecal morphine for pain management
in the MS population. Pregabalin, an isomer of GABA with
selectively binds to the alfa2-delta protein of the voltage-
gated calcium channels, has been shown to be eﬃcacious in
the management of peripheral neuropathic pain of various
causes including MS [80, 81].
5.1.5. Cognitive Deﬁcits. Current estimates of prevalence of
neuropsychological problems in MS are approximately 50%
[82, 83]. The neurocognitive and behavioural deﬁcits in MS,
and suggested treatments are discussed in a recent review
[84]. Cognitive problems result from aﬀected pathways in
the cerebral white matter (limbic system, the midbrain,
and brainstem), which transmit to, and communicate with,
higher-level cortical regions throughout the brain. These
deﬁcits can be a major impediment to rehabilitation and
include: inability to store and to retrieve information,
decreased memory, attention and speed of processing, and
limitations in emotion, personality, and behaviour [84–86].
Many guidelines exist for neuropsychological research
in MS [84]. Neuropsychological interventions are designed
to enhance a person’s ability to function in all areas
of family and community life, which are meaningful for
pwMS. A neuropsychological assessment can be helpful to
delineate problems and suggest compensatory techniques.
These include functionally oriented therapies based on
speciﬁc deﬁcits: compensatory strategies (using intact skills
or external aids to improve function), substitution (learnt
use of intact cognitive abilities to circumvent a problem), or
scheduling (templates and structured programs) may assist
with everyday living tasks.
A systematic review reported that cognitive behaviour
therapies (CBT) were beneﬁcial for pwMS in terms of
coping with, and adjustment to MS [33]. Other speciﬁc
cognitive rehabilitation protocols are being evaluated [87].
Althoughtheevidenceforindividualinterventionsislimited,
computer-based retraining program was shown to improve
deﬁcits related to attention [88]. Medications such as
amantadine, glatiramer acetate, memantine, and donepezil
failed to improve cognitive function in MS [89–92]; others
such as methylphenidate have not yet been studied in pwMS.
5.1.6. Visual and Brainstem Symptoms. Visual disturbances
were reported by 58% of pwMS in one large cohort [93].
Referral to “low vision clinic” may be required for decreased
visual acuity (optic neuritis). The visual dysfunction may
also result from involuntary eye movement disorders (nys-
tagmus and opsoclonus) [28]. Patient education, use of
adaptive visual aids (prisms and magnifying lens), and
occasionally medications such as baclofen, isoniazid, and
gabapentin may be helpful for involuntary eye movements
[94]. Referral to occupational therapy and low vision clinics
can be helpful for neuromobility services such as practicing
outdoor mobility to improve safe community access.
Vestibular involvement in MS is frequent and causes ver-
tigo and often associated with other signs of brainstem dys-
function. Speciﬁc vestibular physiotherapy exercises (such
as Cawthorne-Cooksey protocol) may be helpful. Eﬀective
speech therapy for dysarthria for MS includes control of
speech rate, voice emphasis and power, and reduction in
phrase length [95–97]. Dysphagia occurs in about 34%–43%
of pwMS [98, 99]. Fatigue, tremors, weakness, and incoor-
dination exacerbate dysphagia and dysarthria. Spasticity is
worsened by malnutrition. For the most severely aﬀected
pwMS, maintenance of nutritional balance may require
placement of a percutaneous peg for feeding. This requires
specialized nutritional and speech pathology services. Vide-
oﬂuoroscopy and clinical assessment is recommended for
more disabled persons [100]. Speech therapy can provide
compensatory strategies to avoid aspiration, correct posture
(sitting up when eating), alter food consistency, and provide
education to prevent complications (pneumonia) [99].
5.1.7. Psychiatric and Psychological Dysfunction. The preva-
lence of major depressive disorder in pwMS is reportedly
between 27%–54%, and nearly double the prevalence in
persons without MS over 12 months (15.7% versus 7.4%)
[101]. There was also an age eﬀect, with a prevalence of 25%
in adults between 18 and 45 years. The relationship between
depression and cognitive dysfunction, and treatment are dis-
cussed elsewhere [71]. Depression impacts’ on all aspects of
life and can amplify symptoms, leading to further limitation
in function, and interferes with disease management [102].
Major depressive disorder is linked to objective cognitive
diﬃculties (attention and memory) [103].
Selective serotonin reuptake inhibitors are widely used
to treat depression in rehabilitation. One study (n = 630)
comparedCBT,theantidepressantSertraline,andgrouppsy-
chotherapy [104]. CBT and Sertraline were more eﬃcacious18 Neurology Research International
than group therapy, and improvement in depressive symp-
toms persisted at 6-month followup. Symptoms of depres-
sion also improved in persons who received an alternate
approach—an eight-week telephone cognitive behavioural
intervention compared to usual care [105]. This approach
was adapted to address barriers such as transportation and
access pwMS. Exercise improves mood, fatigue and QoL
[105, 106] and is as eﬀective as standard antidepressant
medication and psychotherapy [107].
Other approaches to treat depression include behaviour
activation (which treats depression by increasing access
to positive reinforcement and decreasing frequency and
intensity of aversive events and consequences) [108]a n d
interpersonal therapy—an evidence based approach that
focus’ on role disputes and role transitions as a framework
for therapy [109].
Psychosocial issues include inability to cope (patient
and family), stress, ﬁnancial considerations, and marital
discord. ArecentAustralianstudy outlined factorsimpacting
on MS caregivers in a community setting [110]. More
strain was reported in caregivers caring for pwMS with
depression, anxiety, and stress levels, with a poorer QoL for
both the carer and care recipient. Education and support,
stress management, and coping skills can positively inﬂuence
health and wellbeing and may require clinical psychology
and psychiatry. Neuropsychological counselling improved
insight and social skills training compared with standard
counselling, in reducing disinhibition and socially aggressive
behaviour especially in cognitively impaired pwMS [111].
5.1.8. General Reconditioning and Ambulation. Reduced
physical activity and exercise due to MS limitations have
been discussed elsewhere [112]. Causal factors include
decreased muscle strength, aerobic capacity, maximal vital
capacity, and increase in neuromuscular tension, fatigue,
anxiety, and depression. Exercise programs do not alter
the MS disease course but do prevent secondary eﬀects of
inactivity and improve fatigue and sense of well-being. An
integrated exercise program incorporates: a daily passive
range of motion, an active range of motion with gravity
eliminated or against gravity as allowed by strength, and
speciﬁc muscle training (three sets of 10 repetitions) is
recommended for focal weakness, when fatigue and heat
sensitivity are issues [112, 113]. Active exercise for 20–30
m i n u t e s3t i m e sp e rw e e k ,w i t ha5m i n u t ew a r m u pa n d
cool-down, stretching for lower limbs and back is eﬀective
[112], while aerobic exercises for cardiovascular ﬁtness are
important for overweight persons [114].
Gait is impaired by weakness, spasticity, incoordination,
balance, fatigue, and visual disturbances. For ambulation, a
g r a d e dp r o g r a ms h o u l di m p r o v et r u n kc o n t r o la n db a l a n c e ,
followed by normalizing tone, ﬂexibility, and range of
motion and then strength. Graded sitting and standing
tolerance program and tilt table routine prior to gait training
may be required. Proprioceptive, tactile, and visual cues are
also helpful. Speciﬁc ambulation aids (elbow crutches, walk-
ing frames, and ankle foot orthoses) and mobility devices
(wheel chairs and scooters) can decrease energy expendi-
ture and improve safety and endurance [115]. A person’s
strength, motor control, cognition, and emotional response
are all considered prior to prescription. Wheelchairs are
customized for each person, such as appropriate seating,
posture support, tilt in space mechanism, and manipulation
of components (arm rests, foot plates). Scooters assist those
withataxiaandfatigue.Weightedwristcuﬀsandwalkersmay
help dampen tremors [116].
5.1.9. Activities of Daily Living. Improvement in functional
independence and maintenance is a key rehabilitation goal.
Principles of occupational therapy (OT) in MS have been
previously discussed [117]. OT was eﬀective in improving
function in pwMS, using retraining techniques for personal,
domestic, and community tasks, mainly in inpatient settings
[34]. However, in a recent systematic review [31] patient
education and energy conservation strategies in MS were
found to be inconclusive due to methodological weakness
of included studies. OT should concentrate on activities
that pwMS would use in practice, rather than on activities
that people may not value because of environmental or
behavioural circumstances [85].
5.1.10. Driving. Although a recent study did not ﬁnd
excessive risk for fatal road accidents in pwMS [118],
many issues impact on driving, especially cognitive and
perceptual considerations [119]. Driving assessments may be
required based on each individual’s deﬁcits. In persons with
PPMS, if there are concerns, then a driving assessment by
the occupational therapist is recommended. Fatigue-related
issues due to MS may impact on the ability of the pwMS to
drive for 45 minutes without a break—this has implications
for holding a full driving license (Australia). Restrictions
such as driving during day time only (poor night vision) or
driving in localized area may be required. For more severely
aﬀected individuals, other specialized driving adaptations
such as hand brakes, use of spinner knob on driving wheel,
extra rear view mirrors, and motorized pulleys for folding
and storage of wheelchairs may be needed.
5.1.11. Employment. An estimated 65% of pwMS were
working at the time of their diagnosis, and between 25%
and 35% of these persons remain in work force 5–10 years
of diagnosis [120]. Fatigue, urinary urgency and inconti-
nence, and visual and mobility issues are the main barriers
for continued employment. Many pwMS leave workforce
prematurely, or on advice of a well-meaning health care
provider or family member. Rehabilitation input may assist
in continued employment. Reasonable accommodations for
MS include ﬂexible working hours, work at home options,
transportation, accessible work environment (bathroom,
desk), memory aids (planners and diaries), vision aids
(voice recognition software), and air-conditioning. Return-
to-work programs are customized, graded (gradual increase
in working hours), or altered to suit the individual with MS
[121]. These programs are coordinated by the Vocational
Rehabilitation Services, in collaboration with the employee,
employer and the treating rehabilitation team. Vocational
rehabilitation interventions for pwMS focus on job retentionNeurology Research International 19
strategies rather than retraining for new jobs. There are a
very limited number of high-quality studies at present that
address the eﬃcacy of vocational rehabilitation in the MS
population. A recent review, therefore, found insuﬃcient
evidence as yet to support vocational rehabilitation in pwMS
[122].
6. Summary
The multiple concurrent MS-related physical, cognitive,
emotional, and social issues make rehabilitation challenging
in persons with PPMS. Rehabilitation measures do not alter
the course of MS disease. The overriding principle in setting
goals for a pwMS is to maximize functional independence
and safety, minimize complications and problems that result
from decreased mobility, compensate for loss of function,
and improve quality of life. With disease progression a
“neuropalliative”approachisrequired.Rehabilitationshould
be viewed as an ongoing process to anticipate problems and
to maintain and restore maximum function and QoL for
persons with PPMS.
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